Short answer
Nuvation Bio Inc. (NUVB) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $45M (up 242.6% year over year) with net income of −$42M.
Q3 2026 key financials · XBRL
- Revenue
- $45M
- +242.6% YoY · +41.9% QoQ
- Net income
- −$42M
- +24.9% YoY · +33.3% QoQ
- Operating margin
- -93.9%
- EPS (diluted)
- −$0.11
- +31.3% YoY · +38.9% QoQ
Source: XBRL data from the Nuvation Bio Inc. (NUVB) Q3 2026 10-Q on SEC EDGAR. USD.
Nuvation Bio Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $44.951M, up $31.831M YoY from $13.120M
- Product revenue $27.457M, up from $7.723M; collaboration revenue $17.494M, up from $5.397M
- Q3 operating margin -93.9% vs -429.8% YoY, based on total costs and expenses
- Cash $663.4M at September 30, 2026; operating cash outflow $76.461M for nine months
- $279.1M net convertible-note proceeds, $58.7M debt repayment, $17.1M capped-call cost; liquidity expected through at least 12 months
Risk Factors
- Newly added debt risk: $287.5 million of 0.75% Convertible Senior Notes due 2032 issued in July 2026
- Most material commercialization risk: IBTROZI became the sole FDA-approved product after June 2025 approval, concentrating near-term revenue dependence
- Regulatory risk: U.S. approval requires pediatric, hepatic impairment, drug interaction and companion-diagnostic post-marketing commitments
- Operational risk: Single-source taletrectinib API supply while developing a second source
- Liquidity risk: $663.4 million cash and investments expected to fund operations for at least 12 months, subject to operating-plan assumptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvation Bio Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.